Medications Associated with Pancreatitis

High-Risk Medications

The European Crohn's and Colitis Organisation recommends that azathioprine and 6-mercaptopurine be used with caution due to the risk of dose-independent pancreatitis, which occurs in approximately 4% of treated IBD patients, typically within 3-4 weeks of treatment initiation 1, 2
The American Gastroenterological Association notes that GLP-1 receptor agonists, such as semaglutide, dulaglutide, and liraglutide, have been associated with acute pancreatitis, although causality has not been definitively established, and recommends discontinuing these medications if pancreatitis is suspected 3, 4, 5
The American Diabetes Association recommends that DPP-4 inhibitors, such as sitagliptin, saxagliptin, alogliptin, and linagliptin, be used with caution due to the risk of pancreatitis, and recommends discontinuing these medications if pancreatitis is suspected 4, 6

The European Crohn's and Colitis Organisation notes that IBD patients, particularly those with Crohn's disease, are at higher risk of thiopurine-induced pancreatitis 1, 2
The American Gastroenterological Association recommends that patients carrying the HLA-DQA102:01-HLA-DRB107:01 haplotype be monitored closely for thiopurine-induced pancreatitis due to their increased risk 1

The American College of Gastroenterology notes that drug-induced pancreatitis typically presents similarly to other forms of acute pancreatitis, with symptoms including upper abdominal pain, elevated serum lipase/amylase, and consistent abdominal imaging 1

The European Crohn's and Colitis Organisation recommends careful monitoring during the first few weeks of therapy with high-risk medications, particularly thiopurines, to minimize the risk of pancreatitis 1, 2
The American Gastroenterological Association recommends considering alternative medications in patients with other risk factors for pancreatitis, such as gallstones or alcohol use 1

The Centers for Disease Control and Prevention recommends caution with didanosine due to its association with pancreatitis, with fatal and nonfatal cases reported in HIV-positive patients 7
The American Diabetes Association notes that GLP-1 receptor agonists, such as semaglutide, liraglutide, and tirzepatide, have been associated with pancreatitis, though causality has not been definitively established 8
The American Diabetes Association also suggests that GLP-1 receptor agonists may have a potential risk of pancreatitis, as evidenced by multiple reports 9
The National Kidney Foundation indicates that DPP-4 inhibitors, such as sitagliptin and saxagliptin, have been linked to pancreatitis 10

The Centers for Disease Control and Prevention warns that combination therapy with didanosine and stavudine may increase the risk of pancreatitis 7
The American Academy of Family Physicians notes that certain drug combinations, such as didanosine with stavudine, may increase the risk of pancreatitis 11
The National Kidney Foundation advises that patients with renal impairment may have an increased risk of pancreatitis due to drug accumulation 10